DelveInsight’s “Candidemia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Candidemia pipeline landscapes. It comprises Candidemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Candidemia pipeline products.
Some of the key takeaways of the Candidemia Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such asAmplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, etc., are developing therapies for the treatment of Candidemia.
-
Emerging therapies such as APX001, CD101, SCY-078, are expected to have a significant impact on the Candidemia market in the coming years.
-
The market Size of candidemia in the 7MM was found to be USD 2,263.1 million in 2017.
-
Among the 7MM, the US accounted for 49.6% of the overall market size of candidemia in 2017.
Get an overview of pipeline landscape @ Candidemia Clinical Trials Analysis
Candidemia is the most common fungal bloodstream infection and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.
Candidemia Emerging Drugs
-
APX001 by Amplyx Pharmaceuticals
-
CD101 by Cidara Therapeutics
-
SCY-078 by Scynexis
-
And others.
Scope of Candidemia Pipeline Drug Insight
-
Coverage: Global
-
Major Players:Amplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, and others.
-
Pipeline Therapies: APX001, CD101, SCY-078, and others.
Table of Contents
|
1 |
Candidemia Report Introduction |
|
2 |
Candidemia Executive Summary |
|
3 |
Candidemia Overview |
|
4 |
Candidemia- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Candidemia Pipeline Therapeutics |
|
6 |
Candidemia Late Stage Products (Phase II/III) |
|
7 |
Candidemia Mid Stage Products (Phase II) |
|
8 |
Candidemia Early Stage Products (Phase I) |
|
9 |
Candidemia Preclinical Stage Products |
|
10 |
Candidemia Therapeutics Assessment |
|
11 |
Candidemia Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Candidemia Key Companies |
|
14 |
Candidemia Key Products |
|
15 |
Candidemia Unmet Needs |
|
16 |
Candidemia Market Drivers and Barriers |
|
17 |
Candidemia Future Perspectives and Conclusion |
|
18 |
Candidemia Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Candidemia Drugs Pipeline Report
Related Reports:
Candidemia Market
DelveInsight’s Candidemia – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Candidemia Epidemiology
DelveInsight’s ‘ Candidemia- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Candidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/